Monitoring neonatal fungal infection with metabolomics

Dessì, Angelica; Liori, Barbara; Caboni, Pierluigi; Corsello, Giovanni; Giuffrè, Mario; Noto, Antonio; Serraino, Francesca; Stronati, Mauro; Zaffanello, Marco; Fanos, Vassilios

doi:10.3109/14767058.2014.954787

Cited by 26 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fungal sources of neonatal sepsis commonly include C. albicans and C. parapsilosis . Symptoms of fungal neonatal sepsis are ambiguous, as described above 83 . Using GC-MS, researchers found increased levels of N-glycine, D-serine, L-threonine, and D-glucose in septic urine, while citric acid, hexadecanoic acid, and octadecanoic acid were found at decreased levels.…”

Section: Metabolomicsmentioning

confidence: 99%

Mass spectrometry for the discovery of biomarkers of sepsis

Ludwig

Hummon

2017

Mol. BioSyst.

View full text Add to dashboard Cite

Sepsis is a serious medical condition that occurs in 30% of patients in intensive care units (ICUs). Early detection of sepsis is key to prevent its progression to severe sepsis and septic shock, which can cause organ failure and death. Diagnostic criteria for sepsis are nonspecific and hinder a timely diagnosis in patients. Therefore, there is currently a large effort to detect biomarkers that can aid physicians in the diagnosis and prognosis of sepsis. Mass spectrometry is often the method of choice to detect metabolomic and proteomic changes that occur during sepsis progression. These “omics” strategies allow for untargeted profiling of thousands of metabolites and proteins from human biological samples obtained from septic patients. Differential expression of or modifications to these metabolites and proteins can provide a more reliable source of diagnostic biomarkers for sepsis. Here, we focus on the current knowledge of biomarkers of sepsis and discuss the various mass spectrometric technologies used in their detection. We consider studies of the metabolome and proteome and summarize information regarding potential biomarkers in both general and neonatal sepsis.

show abstract

Section: Metabolomicsmentioning

confidence: 99%

Mass spectrometry for the discovery of biomarkers of sepsis

Ludwig

Hummon

2017

Mol. BioSyst.

View full text Add to dashboard Cite

show abstract

“…In a study of neonates with fungal infections, the amino acid serine was elevated compared with healthy controls, and levels gradually declined in response to antifungal therapy, providing treatment-specific feedback before the time when culture results would be finalized. 58 In animal studies, expressed metabolites differed in mice receiving effective versus ineffective antibiotic treatment against the bacterium Staphylococcus aureus within 2 hours after initiation of therapy. 47 The same authors were able to demonstrate similar changes in response to therapy in vivo, in both S. aureus and Escherichia coli infections.…”

Section: Precision Medicine and Drug Targets For Sepsismentioning

confidence: 99%

Metabolomics as a Driver in Advancing Precision Medicine in Sepsis

et al. 2017

View full text Add to dashboard Cite

Objective The objective of this review is to explain the science of metabolomics—a science of systems biology that measures and studies endogenous small molecules (metabolites) that are present in a single biological sample—and its application to the diagnosis and treatment of sepsis. In addition, we discuss how discovery through metabolomics can contribute to the development of precision medicine targets for this complex disease state and the potential avenues for those new discoveries to be applied in the clinical environment. Methods A nonsystematic literature review was performed focusing on metabolomics, pharmacometabolomics, and sepsis. Human (adult and pediatric) and animal studies were included. Main Results Metabolomics has been investigated in the diagnosis, prognosis, and risk stratification of sepsis, as well as for the identification of drug target opportunities. Metabolomics elucidates a new level of detail, when compared with other systems biology sciences, with regard to the metabolites that are most relevant in the pathophysiology of sepsis, as well as highlighting specific biochemical pathways at work in sepsis. Metabolomics also highlights biochemical differences between sepsis survivors and nonsurvivors at a level of detail greater than that demonstrated by genomics, transcriptomics, or proteomics, potentially leading to actionable targets for new therapies. The application of pharmacometabolomics and its integration with other systems pharmacology to sepsis therapeutics could be particularly helpful in differentiating drug responders and nonresponders and furthering knowledge of mechanisms of drug action and response. Conclusion The accumulated literature on metabolomics suggest that it is a viable tool for continued discovery around the pathophysiology, diagnosis and prognosis, and treatment of sepsis in both adults and children, and provides a greater level of biochemical detail and insight than other systems biology approaches. However, the clinical application of metabolomics in sepsis has not yet been fully realized. For this to be achieved, prospective validation studies are needed to translate metabolites from the discovery phase into the clinical utility phase.

show abstract

“…14−16 The noninvasive collection of newborn urine and subsequent ease to address large cohorts, compared to newborn blood, makes it a particularly interesting biofluid in the present context. This has indeed been recognized in reports on the newborn urinary impact of prematurity, 17−20 IUGR, 21−23 large for gestational age (LGA), 22,23 GDM, 3 asphyxia, 11,24,25 respiratory distress syndrome (RDS), 24 meconium aspiration syndrome (MAS), 24 bronchopulmonary dysplasia, 26 IEM, 27 neonatal sepsis, 28 postnatal bacterial, 19 cytomegalovirus, 29 and fungal 30 infections. Most of these studies have considered relatively small cohorts (up to ca.…”

Section: ■ Introductionmentioning

confidence: 99%

Newborn Urinary Metabolic Signatures of Prematurity and Other Disorders: A Case Control Study

et al. 2015

View full text Add to dashboard Cite

This work assesses the urinary metabolite signature of prematurity in newborns by nuclear magnetic resonance (NMR) spectroscopy, while establishing the role of possible confounders and signature specificity, through comparison to other disorders. Gender and delivery mode are shown to impact importantly on newborn urine composition, their analysis pointing out at specific metabolite variations requiring consideration in unmatched subject groups. Premature newborns are, however, characterized by a stronger signature of varying metabolites, suggestive of disturbances in nucleotide metabolism, lung surfactants biosynthesis and renal function, along with enhancement of tricarboxylic acid (TCA) cycle activity, fatty acids oxidation, and oxidative stress. Comparison with other abnormal conditions (respiratory depression episode, large for gestational age, malformations, jaundice and premature rupture of membranes) reveals that such signature seems to be largely specific of preterm newborns, showing that NMR metabolomics can retrieve particular disorder effects, as well as general stress effects. These results provide valuable novel information on the metabolic impact of prematurity, contributing to the better understanding of its effects on the newborn's state of health.

show abstract

Monitoring neonatal fungal infection with metabolomics

Cited by 26 publications

References 17 publications

Mass spectrometry for the discovery of biomarkers of sepsis

Mass spectrometry for the discovery of biomarkers of sepsis

Metabolomics as a Driver in Advancing Precision Medicine in Sepsis

Newborn Urinary Metabolic Signatures of Prematurity and Other Disorders: A Case Control Study

Contact Info

Product

Resources

About